Intrarosa (prasterone)
- Region
- 🇪🇺 EU
- Active substance
- prasterone
- Company
- Endoceutics S.A.
- Status
- Authorised
- Therapeutic area
- Postmenopause
- CHMP opinion
- Thu 09 Nov 2017
- EU approval
- Mon 08 Jan 2018
- Application
- EMEA/H/C/004138
- ATC
- G03XX01
- Official record
- www.ema.europa.eu
Indication
Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.
Regulatory milestones
No milestones recorded in the last year.
Follow Intrarosa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.